Whittier Trust Co. of Nevada Inc. Buys 96 Shares of ICON Public Limited (NASDAQ:ICLR)

Whittier Trust Co. of Nevada Inc. lifted its stake in shares of ICON Public Limited (NASDAQ:ICLR) by 23.1% in the third quarter, HoldingsChannel reports. The fund owned 511 shares of the medical research company’s stock after acquiring an additional 96 shares during the period. Whittier Trust Co. of Nevada Inc.’s holdings in ICON Public were worth $147,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in ICLR. Liontrust Investment Partners LLP lifted its holdings in ICON Public by 19.5% in the 2nd quarter. Liontrust Investment Partners LLP now owns 119,728 shares of the medical research company’s stock worth $37,531,000 after purchasing an additional 19,546 shares in the last quarter. Kornitzer Capital Management Inc. KS lifted its holdings in ICON Public by 15.9% in the 2nd quarter. Kornitzer Capital Management Inc. KS now owns 95,753 shares of the medical research company’s stock worth $30,016,000 after purchasing an additional 13,163 shares in the last quarter. Whittier Trust Co. lifted its holdings in ICON Public by 12.3% in the 3rd quarter. Whittier Trust Co. now owns 4,020 shares of the medical research company’s stock worth $1,155,000 after purchasing an additional 441 shares in the last quarter. Sara Bay Financial purchased a new position in ICON Public in the 3rd quarter worth approximately $1,143,000. Finally, Motco lifted its holdings in ICON Public by 1.5% in the 1st quarter. Motco now owns 3,882 shares of the medical research company’s stock worth $1,304,000 after purchasing an additional 59 shares in the last quarter. 95.61% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on ICLR shares. Redburn Atlantic started coverage on ICON Public in a report on Monday, October 14th. They set a “neutral” rating and a $311.00 price objective on the stock. Robert W. Baird decreased their price objective on ICON Public from $368.00 to $340.00 and set an “outperform” rating on the stock in a report on Friday, September 20th. Leerink Partners started coverage on ICON Public in a report on Wednesday, September 18th. They set an “outperform” rating and a $379.00 price objective on the stock. Leerink Partnrs raised ICON Public to a “strong-buy” rating in a report on Wednesday, September 18th. Finally, Truist Financial decreased their price objective on ICON Public from $383.00 to $363.00 and set a “buy” rating on the stock in a report on Monday, October 14th. Two equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $346.09.

ICON Public Stock Performance

NASDAQ:ICLR opened at $280.76 on Thursday. The stock’s fifty day moving average is $302.52 and its 200 day moving average is $311.80. ICON Public Limited has a fifty-two week low of $222.32 and a fifty-two week high of $347.72. The firm has a market capitalization of $23.16 billion, a PE ratio of 34.16, a PEG ratio of 1.35 and a beta of 1.22. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.31 and a current ratio of 1.31.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $3.75 earnings per share for the quarter, beating the consensus estimate of $3.68 by $0.07. The company had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.14 billion. ICON Public had a return on equity of 12.06% and a net margin of 8.57%. ICON Public’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.96 EPS. On average, sell-side analysts anticipate that ICON Public Limited will post 14.54 earnings per share for the current year.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.